Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y.

J Clin Oncol. 2019 Dec 4:JCO1901674. doi: 10.1200/JCO.19.01674. [Epub ahead of print]

PMID:
31800340
2.

Emerging Biomarkers in the Era of Personalized Cancer Medicine.

Ricciuti B, Leonardi GC, Brambilla M.

Dis Markers. 2019 Aug 14;2019:5907238. doi: 10.1155/2019/5907238. eCollection 2019. No abstract available.

3.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
4.

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence.

Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC.

Onco Targets Ther. 2019 Apr 30;12:3171-3179. doi: 10.2147/OTT.S177051. eCollection 2019.

5.

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.

Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R, Pirro M.

Pharmacol Ther. 2019 Apr;196:105-116. doi: 10.1016/j.pharmthera.2018.12.004. Epub 2018 Dec 4. Review.

PMID:
30521884
6.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

7.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

8.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

9.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

10.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM.

J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6.

11.

Cutaneous melanoma: From pathogenesis to therapy (Review).

Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S, Libra M.

Int J Oncol. 2018 Apr;52(4):1071-1080. doi: 10.3892/ijo.2018.4287. Epub 2018 Feb 27. Review.

12.

Ageing: from inflammation to cancer.

Leonardi GC, Accardi G, Monastero R, Nicoletti F, Libra M.

Immun Ageing. 2018 Jan 19;15:1. doi: 10.1186/s12979-017-0112-5. eCollection 2018. Review.

13.

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.

J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173.

PMID:
28557813
14.

The safety of nivolumab for the treatment of advanced non-small cell lung cancer.

Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R.

Expert Opin Drug Saf. 2017 Jan;16(1):101-109. Epub 2016 Dec 11. Review.

PMID:
27910704
15.

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Ricciuti B, Metro G, Leonardi GC, Sordo RD, Colella R, Puma F, Ceccarelli S, Potenza R, Rebonato A, Maiettini D, Crinò L, Chiari R.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000514.

PMID:
27133228
16.

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient.

Ricciuti B, Leonardi GC, Ravaioli N, De Giglio A, Brambilla M, Prosperi E, Ribacchi F, Meacci M, Crinò L, Maiettini D, Chiari R, Metro G.

J Breast Cancer. 2016 Sep;19(3):324-329. Epub 2016 Sep 23.

17.

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.

Ricciuti B, Leonardi GC, Metro G, Grignani F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A, Zicari D, Crinò L.

Expert Rev Respir Med. 2016;10(1):53-68. doi: 10.1586/17476348.2016.1115349. Epub 2015 Nov 17. Review.

PMID:
26714748
18.

miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.

Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, Chiari R, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G.

Ecancermedicalscience. 2015 Sep 2;9:569. doi: 10.3332/ecancer.2015.569. eCollection 2015.

19.

Paraneoplastic cerebellar degeneration associated with ovarian cancer.

Russo AE, Scalone S, Leonardi GC, Scalisi A, Giorda G, Sorio R.

Oncol Lett. 2013 Feb;5(2):681-683. Epub 2012 Nov 7.

20.

microRNAs and thyroid cancer: biological and clinical significance (Review).

Leonardi GC, Candido S, Carbone M, Colaianni V, Garozzo SF, Cinà D, Libra M.

Int J Mol Med. 2012 Nov;30(5):991-9. doi: 10.3892/ijmm.2012.1089. Epub 2012 Aug 8. Review.

PMID:
22895530
21.

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).

Leonardi GC, Candido S, Carbone M, Raiti F, Colaianni V, Garozzo S, Cinà D, McCubrey JA, Libra M.

Mol Med Rep. 2012 Oct;6(4):687-94. doi: 10.3892/mmr.2012.1016. Epub 2012 Aug 2. Review.

PMID:
22858857
22.

Correlation of the risk of breast cancer and disruption of the circadian rhythm (Review).

Leonardi GC, Rapisarda V, Marconi A, Scalisi A, Catalano F, Proietti L, Travali S, Libra M, Fenga C.

Oncol Rep. 2012 Aug;28(2):418-28. doi: 10.3892/or.2012.1839. Epub 2012 May 29. Review.

PMID:
22664950
23.

The tumor microenvironment in hepatocellular carcinoma (review).

Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, Spandidos DA, Libra M.

Int J Oncol. 2012 Jun;40(6):1733-47. doi: 10.3892/ijo.2012.1408. Epub 2012 Mar 22. Review.

PMID:
22447316

Supplemental Content

Loading ...
Support Center